Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
SARS-CoV-2 Pneumonia, COVID-19
About this trial
This is an interventional treatment trial for SARS-CoV-2 Pneumonia focused on measuring SARS-CoV-2, Pneumonia, Hydroxychloroquine, COVID-19
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years of age
- SARS-CoV-2 positive per FDA approved RT-PCR (reverse transcription-polymerase chain reaction)
- Acute hypoxia (O2 sat < 90 % or paO2 < 60 on room air), or above baseline chronic O2 requirement
- Inpatient admission
Exclusion Criteria:
- Requires supplemental O2 >10 litres per minute or mechanical ventilation on admission
- Pregnancy
- AST/ALT > 5 times the upper limit normal
- Baseline prolonged QT
- Child-Pugh Score B or greater
- ESRD(end-stage renal disease) requiring dialysis
- Known allergy to medication component,
- History of severe G6PD (glucose-6-phosphate dehydrogenase)
- Myasthenia gravis
- Porphyria
- Ongoing treatment for epilepsy
- Life expectancy < 6 months,
- Patient lacks capacity to provide consent and does not have a surrogate decision maker.
- Retinal Disease
Sites / Locations
- Kootenai Health
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Hydroxychloroquine (HCQ)
Usual Care
Initial dose: HCQ 400mg x 2 (800mg) then 200mg by mouth, three times per day (600mg/24hr period) starting 8 hours after the initial dose for a total of 14 doses over 5 days Plus Usual Care (See below for full description)
The care of hospitalized patients with covid-19 is evolving with hospital guidelines arising across the U.S. with several commonalities. Patients receive clinical assessment, chest x-ray, covid-19 testing, basic labs (WBC, CMP), and additional labs based on protocol or clinical judgment (ABG, CRP, LDH), antibiotics for possible bacterial pneumonia, acetaminophen for fever, supplemental O2, and consideration for mechanical ventilation. Early intubation over escalating noninvasive support. Low tidal volume ventilation and prone positioning are lung protective strategies used in critically ill covid-19 patients that are based on management of acute respiratory distress syndrome generally. Conservative fluid replacement is used to avoid worsening oxygenation.